Body fat changes and risk of new onsets of hypertension and hyperlipidaemia among Korean adults: a longitudinal study

Clinical Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 100293 - 100293

Published: Feb. 1, 2025

This study examined the association between changes in body fat, mass index (BMI), and risk of newly developed hypertension hyperlipidaemia general population. longitudinal included 17,598 individuals without prior who underwent at least three health examinations January 2015 December 2022. Body fat was classified as decreased (≥ 5 %), stable (within increased %) using bioelectrical impedance analysis. The BMI categorised non-obese (BMI < 23), overweight (23 ≤ 25), obese ≥ 25). Hypertension were identified through self-reported medication use or clinical measurements. Increases associated with higher incidence rates hyperlipidaemia. Decreased a lower (Odds ratio: 0.638, 95 % confidence interval: 0.464-0.876) groups (0.724, 0.577-0.909). Non-obese had than (87.2 vs 66.4 per 1,000 people). Compared to group, raised (non-obese: 1.522, 1.248-1.855; overweight: 1.278, 1.032-1.583; obese: 1.214, 1.028-1.433). Overweight demonstrated (0.546, 0.400-0.747). Increased hyperlipidaemia, even within same category. Decreasing particularly individuals, is

Language: Английский

---

The effects of smoking, alcohol consumption, obesity, and physical inactivity on healthcare costs: a longitudinal cohort study

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 5, 2025

Research indicates major risk factors including smoking, alcohol consumption, obesity and physical inactivity contribute significantly to global disease burden healthcare costs. However, these studies have challenges, such as increased bias uncertainty arising from use of population attributable fractions (PAF) the issue reverse causality in cross-sectional data. This study aims evaluate long-term costs associated with behaviors using a longitudinal cohort. cohort used Korean National Health Insurance Service-National Sample Cohort database (NHIS-NSC 2.0), covering 2002-2019. The included individuals aged 40-69 years who underwent health examinations 2002-2004 had no pre-existing factor-related diseases. Cumulative during 2010-2019 were analyzed generalized linear model log-link function gamma distribution, adjusted for other sociodemographic factors. Smoking, obesity, both sexes. Male current smokers incurred 13.8% higher than never-smokers, while female spent 18.6% more. Former lower smokers, reductions 9.9% males 13.2% females. Almost daily consumption raised by 21.4% 31.8% Costs varied BMI categories, severe increasing expenditures 26.9% 46.5% females compared normal weight. Overweight status showed contrasting effects between sexes, 3.4% decrease but 7.6% increase Exercising 1-4 times weekly reduced 7.4% non-exercisers. underscores economic impact supports need targeted public interventions. findings highlight importance interventions high-risk groups reducing

Language: Английский

---

Current State of Pharmacotherapy in Obesity

Korean Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 83(3), P. 94 - 101

Published: March 25, 2024

The prevalence of obesity with various complications is increasing rapidly in Korea.Although lifestyle modification fundamental treatment, more effective treatment tools are required.Many advances have been reported recently, including modifications and pharmacological, endoscopic, surgical treatments.Drugs proven long-term efficacy safety preferred because management for a process.Currently, four medications available use Korea: Orlistat, Naltrexone/bupuropion NR, Phentermine/topiramate capsule, Liraglutide.Recently, semaglutide tirzepatide attracting attention their effectiveness convenience, but they not yet Korea.In addition, there limitations such as the yo-yo effect when discontinuing drug, safety, cost.Patients medical staff must be aware advantages side effects each medication to ensure successful obesity.(

Language: Английский

---

The role of incretin receptor agonists in the treatment of obesity

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(10), P. 4178 - 4196

Published: July 29, 2024

Abstract Introdroduction Obesity and its associated metabolic conditions have become a significant global health problem in recent years, with many people living obesity fulfilling criteria for pharmacological treatment. The development of the glucagon‐like peptide‐1 receptor agonists chronic weight management has triggered new interest incretins other hormones as targets obesity, investigations into dual triple co‐agonists. Methods objective this narrative review was to summarize available data on approved emerging incretin‐based agents treatment obesity. Results In clinical trials currently overweight or loss between 6% 21% baseline body been observed, 23% 94% participants achieving 10% higher loss, depending study agent used. Favourable outcomes also seen regard cardiovascular risk outcomes, diabetes prevention, dysfunction‐associated steatotic liver disease/steatohepatitis prevention regain after surgery. Limitations these include high costs, potential once is stopped, lean mass gastrointestinal adverse events; issues respect gallbladder biliary diseases require further investigation. Conclusions Many co‐agonists are still development, more needed assess efficacy, safety tolerability therapies versus established therapies; however, promising, results eagerly awaited.

Language: Английский

---

Non-alcoholic fatty liver disease and LV diastolic dysfunction in patients with type 2 diabetes mellitus.

PubMed, Journal Year: 2025, Volume and Issue: 16(1), P. 47 - 57

Published: Jan. 1, 2025

To date, the clinical implications of long-lasting non-alcoholic fatty liver disease (NAFLD) such as left ventricular diastolic dysfunction (LVDD) in course type 2 diabetes mellitus (T2DM) are yet to be determined. The main aim this study was investigate correlation between NAFLD and early LVDD progression along with demographic characteristics.

Language: Английский

---

Inverse association between obesity and suicidal death risk

BMC Psychiatry, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 8, 2025

Abstract Background Suicide is a significant yet preventable public health issue. Body mass index (BMI) readily measurable indicator associated with various outcomes. However, the relationship between BMI and suicidal death risk complex warrants further investigation, particularly within contemporary, non-Western contexts consideration of potential confounders. The purpose this study was to investigate death. Methods This nationwide, retrospective, observational based on Korean National Health Insurance Service database. We analyzed 4,045,081 participants who were aged > 19 years underwent national surveillance in 2009. categorized according their (underweight: < 18.5 kg/m², normal weight: 18.5–23 overweight: 23–25 class I obesity: 25–30 II 30 kg/m²). primary outcome events caused by suicide which defined International Classification Disorders (ICD-10) codes (X60–X84) records documented Korea Statistical Office. Multivariate Cox proportional hazard regression analysis performed estimate respect categories after adjusting for confounders (age, sex, income, diabetes, hypertension, dyslipidemia, smoking, drinking, exercise, self-abuse, waist circumference, schizophrenia, bipolar disorder, eating cancer, anxiety, substance use disorder). Results Underweight individuals had an increased (hazard ratio [HR] 1.44, 95% confidence interval [CI] 1.31–1.57) while overweight (HR 0.79, CI 0.76–0.83), 0.76, 0.71–0.80) obesity 0.71, 0.63–0.81) decreased risks deaths compared those weight (BMI 18.5–23). trend consistent regardless presence major depressive disorder (MDD) or type living arrangements participants. Conclusions Suicidal inversely correlated categories, independent MDD arrangements. Our data suggests importance physiological factors body understanding risk. Furthermore, these provide valuable insights where resources should be invested reduce rates.

Language: Английский

---

An anonymized, de-identified registry study protocol to determine the effectiveness and safety of weight loss with enavogliflozin in patients with type 2 diabetes mellitus

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(1), P. e0315603 - e0315603

Published: Jan. 22, 2025

Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety effectiveness. This study aims evaluate effects of weight loss enavogliflozin administration in T2D a setting over 24 weeks. large-scale, prospective, multicenter, non-interventional observational will be conducted 12 primary care centers nationwide between 2024 2026. Data collected at baseline, weeks, weeks setting, demographic details, history, lifestyle habits, medication use, various health indicators. Eligible participants are adults aged 19 80 body mass index (BMI) ≥23 kg/m who currently receiving treatment Envlo (enavogliflozin) or Envlomet (enavogliflozin/metformin) tablets planning start treatment. The outcome change BMI from baseline. Secondary outcomes evaluated changes proportion achieving significant reductions composition improvements analyze shifts lipid profiles, liver kidney functions, exploratory outcomes. For outcomes, trial prioritize monitoring adverse drug reactions specific events interest hypoglycemia, urinary tract infections, genital polyuria, polydipsia. design enables us effectiveness while exploring its potential positive on function risk factors overweight obese T2D.

Language: Английский

---

Defining obesity in the context of cancer: thinking beyond body mass index

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease

Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Language: Английский

---

ACTION Malaysia—perception and barriers to obesity management among people with obesity and healthcare professionals in Malaysia

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 3, 2025

Timely weight loss conversations between healthcare professionals (HCPs) and people with obesity (PwO) can help in effective management. The Awareness, Care, Treatment Obesity maNagement the Asia Pacific region (ACTION APAC) studied attitudes, perceptions, behaviours toward among PwO HCPs nine countries of South Southeast Asia. current study is a subgroup analysis based on Malaysian population, known as ACTION Malaysia (ACTION-MY), aims to explore behaviours, barriers management both HCPs. An online survey dual languages (Malay English) was conducted April 2022 May 1001 adult 200 (general practitioners, endocrinologists, obstetricians/gynaecologists, cardiologists, other appropriate specialities). findings highlighted significant gaps awareness, 57% misclassifying their status normal or overweight. While 68% valued discussing HCPs, success rates remained low. On average, patients made three attempts adulthood, 63% regaining even after maintaining for six months more. Key included insufficient exercise, motivation deficits, poor hunger control. Although 88% recognised chronic disease affecting overall health, patient disinterest, limited awareness treatment options, time constraints hindered intervention. Despite 70% trusting HCPs' medication recommendations, only 10% received prescriptions. This emphasises need enhanced communication PwO, along comprehensive support that includes mental health services. Addressing perception gap regarding responsibility crucial. results suggest culturally contextualised approaches are essential. Our highlight urgent developing strategies policies targeting identified establishing collaborative frameworks enhance within Malaysia's system.

Language: Английский

---